26.98
price up icon0.33%   0.09
after-market After Hours: 26.80 -0.18 -0.67%
loading
Structure Therapeutics Inc Adr stock is traded at $26.98, with a volume of 542.05K. It is up +0.33% in the last 24 hours and down -12.97% over the past month. Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
See More
Previous Close:
$26.89
Open:
$27.27
24h Volume:
542.05K
Relative Volume:
0.66
Market Cap:
$1.51B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-12.15
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
-0.22%
1M Performance:
-12.97%
6M Performance:
-39.59%
1Y Performance:
-39.82%
1-Day Range:
Value
$26.06
$27.44
1-Week Range:
Value
$23.50
$27.68
52-Week Range:
Value
$23.50
$62.74

Structure Therapeutics Inc Adr Stock (GPCR) Company Profile

Name
Name
Structure Therapeutics Inc Adr
Name
Phone
(628) 229-9277
Name
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Name
Employee
148
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
GPCR's Discussions on Twitter

Compare GPCR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GPCR
Structure Therapeutics Inc Adr
26.98 1.51B 0 -100.44M -105.32M -2.22
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
416.96 107.75B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
693.23 76.83B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
659.81 39.72B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
249.16 32.48B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
112.76 27.01B 3.30B -501.07M 1.03B -2.1146

Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-08-25 Initiated Stifel Buy
Dec-04-24 Initiated H.C. Wainwright Buy
Sep-23-24 Initiated Morgan Stanley Overweight
May-21-24 Initiated JP Morgan Overweight
Apr-09-24 Initiated Cantor Fitzgerald Overweight
Oct-19-23 Initiated JMP Securities Mkt Outperform
Jul-27-23 Initiated Piper Sandler Overweight
May-25-23 Resumed Jefferies Buy
Feb-28-23 Initiated BMO Capital Markets Outperform
Feb-28-23 Initiated Guggenheim Buy
Feb-28-23 Initiated Jefferies Buy
Feb-28-23 Initiated SVB Securities Outperform
View All

Structure Therapeutics Inc Adr Stock (GPCR) Latest News

pulisher
Jan 15, 2025

GAMMA Investing LLC Raises Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

Schrödinger Secures $150M Novartis Deal, Advances Three Clinical Programs for 2025 - StockTitan

Jan 13, 2025
pulisher
Jan 12, 2025

Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - Defense World

Jan 12, 2025
pulisher
Jan 10, 2025

Structure Therapeutics (NASDAQ:GPCR) Hits New 1-Year LowShould You Sell? - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Stifel Nicolaus Begins Coverage on Structure Therapeutics (NASDAQ:GPCR) - Defense World

Jan 10, 2025
pulisher
Jan 09, 2025

Structure Therapeutics Inc. (NASDAQ:GPCR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Jan 09, 2025
pulisher
Jan 08, 2025

Stock Market Movers Today • Top Gainers & Losers - Benzinga

Jan 08, 2025
pulisher
Jan 08, 2025

Structure Therapeutics (NASDAQ:GPCR) Shares Gap UpHere's What Happened - MarketBeat

Jan 08, 2025
pulisher
Jan 07, 2025

Stifel analysts initiate Structure Therapeutics stock with buy rating By Investing.com - Investing.com Canada

Jan 07, 2025
pulisher
Jan 04, 2025

State Street Corp Increases Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World

Jan 04, 2025
pulisher
Dec 31, 2024

Structure Therapeutics (NASDAQ:GPCR) Reaches New 1-Year LowShould You Sell? - MarketBeat

Dec 31, 2024
pulisher
Dec 30, 2024

Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 5.5%Here's Why - MarketBeat

Dec 30, 2024
pulisher
Dec 26, 2024

Structure Therapeutics (NASDAQ:GPCR) Trading 5.6% HigherStill a Buy? - MarketBeat

Dec 26, 2024
pulisher
Dec 26, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Purchased by Principal Financial Group Inc. - MarketBeat

Dec 26, 2024
pulisher
Dec 23, 2024

Barclays PLC Boosts Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Dec 23, 2024
pulisher
Dec 22, 2024

Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Time to Buy? - Defense World

Dec 22, 2024
pulisher
Dec 19, 2024

Structure Therapeutics (NASDAQ:GPCR) Shares Up 6.6%Still a Buy? - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Structure Therapeutics (NASDAQ:GPCR) Earns "Buy" Rating from HC Wainwright - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Franklin Resources Inc. Boosts Stake in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

Structure Therapeutics' SWOT analysis: oral obesity drug stock shows promise amid fierce competition - Investing.com

Dec 19, 2024
pulisher
Dec 18, 2024

Merck moves into obesity with deal for Hansoh’s GLP-1 pill - BioPharma Dive

Dec 18, 2024
pulisher
Dec 18, 2024

Structure Therapeutics (NASDAQ:GPCR) Sets New 1-Year LowWhat's Next? - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Structure Therapeutics (NASDAQ:GPCR) Earns Market Outperform Rating from JMP Securities - MarketBeat

Dec 18, 2024
pulisher
Dec 18, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update - Defense World

Dec 18, 2024
pulisher
Dec 18, 2024

Structure Therapeutics Selects Lead Oral Small Molecule for Obesity Treatment - Defense World

Dec 18, 2024
pulisher
Dec 18, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Consensus PT from Brokerages - Defense World

Dec 18, 2024
pulisher
Dec 17, 2024

Structure Therapeutics Advances Obesity Treatment Candidate - TipRanks

Dec 17, 2024
pulisher
Dec 17, 2024

Structure Therapeutics Unveils Breakthrough Oral Obesity Drug, First-in-Class Amylin Agonist Shows Promise - StockTitan

Dec 17, 2024
pulisher
Dec 17, 2024

Mcewen Mining Inc (MUX-N) QuotePress Release - The Globe and Mail

Dec 17, 2024
pulisher
Dec 16, 2024

Structure Therapeutics' SWOT analysis: oral GLP-1 stock faces fierce competition - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

Market Factors: The biggest debatesand risksfor investors looking to outperform in 2025 - The Globe and Mail

Dec 16, 2024
pulisher
Dec 15, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $85.67 Average PT from Analysts - MarketBeat

Dec 15, 2024
pulisher
Dec 14, 2024

Exome Asset Management LLC Makes New $5.27 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Dec 14, 2024
pulisher
Dec 12, 2024

Structure Therapeutics Inc (GPCR-Q) QuotePress Release - The Globe and Mail

Dec 12, 2024
pulisher
Dec 12, 2024

2 ‘Monster’ Stocks To Snap Up Before 2025 - Barchart

Dec 12, 2024
pulisher
Dec 11, 2024

Y Intercept Hong Kong Ltd Makes New $1.79 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Dec 11, 2024
pulisher
Dec 08, 2024

Pier Capital LLC Buys 33,087 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Dec 08, 2024
pulisher
Dec 08, 2024

Wellington Management Group LLP Purchases 221,851 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Dec 08, 2024
pulisher
Dec 08, 2024

Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Here’s Why - Defense World

Dec 08, 2024
pulisher
Dec 07, 2024

FY2024 Earnings Estimate for GPCR Issued By Leerink Partnrs - Defense World

Dec 07, 2024
pulisher
Dec 06, 2024

Brokers Offer Predictions for GPCR FY2024 Earnings - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

Leerink Partnrs Has Bearish Outlook for GPCR FY2025 Earnings - Defense World

Dec 06, 2024
pulisher
Dec 06, 2024

Bank of Montreal Can Has $1.94 Million Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Dec 06, 2024
pulisher
Dec 06, 2024

Structure Therapeutics' SWOT analysis: oral GLP-1 stock shows promise amid fierce competition By Investing.com - Investing.com South Africa

Dec 06, 2024
pulisher
Dec 05, 2024

84,000 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Readystate Asset Management LP - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

Point72 Asset Management L.P. Purchases 820,589 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Dec 05, 2024
pulisher
Dec 05, 2024

Structure Therapeutics' SWOT analysis: oral GLP-1 stock shows promise amid fierce competition - Investing.com India

Dec 05, 2024
pulisher
Dec 05, 2024

Structure CEO on the competitive landscape for oral GLP-1 drugs - CNBC

Dec 05, 2024
pulisher
Dec 04, 2024

Janus Henderson Group PLC Buys 602,609 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Dec 04, 2024
pulisher
Dec 04, 2024

Cinctive Capital Management LP Has $1.41 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat

Dec 04, 2024
pulisher
Dec 03, 2024

Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Up 7.6% in November - MarketBeat

Dec 03, 2024

Structure Therapeutics Inc Adr Stock (GPCR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Structure Therapeutics Inc Adr Stock (GPCR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Lin Xichen
CHIEF SCIENTIFIC OFFICER
Jun 03 '24
Option Exercise
0.34
106,200
36,108
191,907
$18.19
price down icon 0.05%
$30.95
price up icon 0.68%
$72.47
price up icon 0.01%
$366.39
price up icon 1.31%
biotechnology ONC
$205.34
price up icon 1.79%
$112.76
price down icon 0.80%
Cap:     |  Volume (24h):